Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 Opus Genetics’ BIRD-1 trial explores OPGx-BEST1 gene therapy for Best disease, focusing on safety, tolerability, and preliminary efficacy in retinal … Read More at Source. Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook More Share on LinkedIn (Opens in new window) LinkedIn Share on Reddit (Opens in new window) Reddit Share on Tumblr (Opens in new window) Tumblr Share on Pinterest (Opens in new window) Pinterest Share on Telegram (Opens in new window) Telegram Share on WhatsApp (Opens in new window) WhatsApp Like this:Like Loading… Related Tags: BirdNews November 17, 2025 by Pumilo Bird News 0
